Who
Abraham Ceesay
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Rapport Therapeutics; Director, Charles River Laboratories International; Director, Pacira BioSciences; President, Cerevel Therapeutics Holdings; Chief Operating Officer, scPharmaceuticals.
In numbers
- Trades disclosed
- 102
- Buys
- 0
- Sells
- 23
- Bought
- $0
- Sold
- $16.8M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 17 Jan 2018
- Last trade
- 21 Oct 2026
- Last filed
- 23 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Oct 2026filed 23 Oct 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $64K2,210 at $29.16 | filing |
| 7 Oct 2026filed 8 Oct 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $35K1,147 at $30.66 | filing |
| 6 Oct 2026filed 8 Oct 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $108K3,375 at $32.03 | filing |
| 23 Sep 2026filed 24 Sep 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $76K1,952 at $39.05 | filing |
| 23 Sep 2026filed 24 Sep 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $8,570215 at $39.86 | filing |
| 23 Sep 2026filed 24 Sep 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,76543 at $41.05 | filing |
| 23 Sep 2026filed 24 Sep 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $76K1,952 at $39.05 | filing |
| 23 Sep 2026filed 24 Sep 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $8,570215 at $39.86 | filing |
| 23 Sep 2026filed 24 Sep 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $1,76543 at $41.05 | filing |
| 8 Sep 2026filed 9 Sep 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $325K7,141 at $45.56 | filing |
| 8 Sep 2026filed 9 Sep 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $49K1,069 at $46.01 | filing |
| 8 Sep 2026filed 9 Sep 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $325K7,141 at $45.56 | filing |
| 8 Sep 2026filed 9 Sep 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $49K1,069 at $46.01 | filing |
| 25 Aug 2026filed 26 Aug 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $938K18,921 at $49.57 | filing |
| 25 Aug 2026filed 26 Aug 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $938K18,921 at $49.57 | filing |
| 11 Aug 2026filed 12 Aug 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $172K3,664 at $46.90 | filing |
| 11 Aug 2026filed 12 Aug 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $937K19,500 at $48.04 | filing |
| 11 Aug 2026filed 12 Aug 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $282K5,794 at $48.62 | filing |
| 11 Aug 2026filed 12 Aug 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $172K3,664 at $46.90 | filing |
| 11 Aug 2026filed 12 Aug 2026 | RAPP Rapport TherapeuticsBiotechnology | SEC FORM 4 Sold | $937K19,500 at $48.04 | filing |
News
Rapport Therapeutics (NASDAQ:RAPP) CEO Abraham Ceesay Sells 1,147 Shares of Company Stockthemarketsdaily.com · 9 Oct 2026Rapport Therapeutics (NASDAQ:RAPP) Stock: Insider Troy Ignelzi Acquires 5,500 SharesRAPP · dailypolitical.com · 21 Oct 2026Why Is Rapport Therapeutics Stock Trading Higher Today?RAPP · aol.com · 20 Oct 2026Rapport Therapeutics Rockets On Positive, But Mixed, Bipolar DataRAPP · investors.com · 20 Oct 2026
1 headline in the last 90 days name Abraham Ceesay; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.